DDX41 Inhibitors
The chemical class of DDX41 inhibitors encompasses a diverse range of compounds that directly or indirectly modulate the function of DDX41, a critical RNA helicase involved in innate immune responses. Enoxacin stands out as a direct inhibitor, targeting DDX41's ATPase activity and impeding its helicase function. This specific interaction highlights the ability for developing targeted inhibitors to fine-tune the innate immune responses mediated by DDX41. Among the indirect inhibitors, NSC 617145 disrupts the TBK1-IRF3 signaling pathway, influencing DDX41 indirectly by preventing the phosphorylation of IRF3. This interruption attenuates the DDX41-mediated immune response, revealing a strategy for modulating DDX41 activity by targeting key signaling nodes in its pathway. Another indirect inhibitor, 6-Azauridine, perturbs the RIG-I-MAVS signaling axis by inhibiting IMPDH, impacting the synthesis of guanosine nucleotides and diminishing DDX41's activation in antiviral responses. BX-795, Tofacitinib, Digoxin, and others act as indirect inhibitors by targeting diverse signaling pathways upstream of DDX41.
Digoxin, on the other hand, modulates the NF-κB pathway, leading to the transcriptional downregulation of DDX41. This highlights the interconnected regulation of innate immune pathways and provides insights into strategies for attenuating DDX41 expression by targeting upstream signaling events. NSC 697923 disrupts the cGAS-STING axis, providing an indirect avenue for modulating DDX41 activity by targeting key elements in the cytosolic DNA sensing pathway. The compound interferes with TBK1 phosphorylation, hindering the activation of DDX41-mediated immune responses. Leflunomide affects the DHODH-IRF3 signaling axis, connecting metabolic pathways to immune signaling regulation and offering a unique approach for modulating DDX41 activity indirectly. PI-103, AC710, TAK-715, and GSK1070916 act as indirect inhibitors by targeting the PI3K-AKT-mTORC1, AKT-mTORC1, p38 MAPK, and cGAS-STING signaling axes, respectively.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Enoxacin | 74011-58-8 | sc-205670 sc-205670A | 500 mg 1 g | $40.00 $49.00 | 2 | |
Enoxacin, a fluoroquinolone antibiotic, acts as a direct inhibitor of DDX41. It inhibits DDX41's ATPase activity, crucial for its helicase function, by binding to the ATP-binding site. This direct inhibition prevents the unwinding of RNA duplexes by DDX41, leading to the suppression of its RNA recognition and immune signaling functions. Enoxacin's specific interference with DDX41 highlights its potential as a targeted inhibitor for modulating innate immune responses mediated by DDX41. | ||||||
6-Azauridine | 54-25-1 | sc-221082B sc-221082 sc-221082C sc-221082A | 500 mg 1 g 2 g 5 g | $97.00 $159.00 $295.00 $679.00 | ||
6-Azauridine, a pyrimidine analog, serves as an indirect inhibitor of DDX41 by influencing the RIG-I-MAVS signaling axis. It inhibits the enzymatic activity of inosine monophosphate dehydrogenase (IMPDH), disrupting the synthesis of guanosine nucleotides. The reduced guanosine levels impair RIG-I-mediated detection of viral RNA, diminishing the activation of downstream effectors like DDX41. | ||||||
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
BX-795, a PDK1 inhibitor, acts as an indirect inhibitor of DDX41 by affecting the mTORC1 signaling pathway. It inhibits PDK1, disrupting the phosphorylation of AKT and downstream mTORC1 activation. The impaired mTORC1 signaling attenuates DDX41 expression, as DDX41 is downstream of mTORC1. | ||||||
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $143.00 $694.00 | ||
12β-Hydroxydigitoxin, a cardiac glycoside, acts as an indirect inhibitor of DDX41 by influencing the NF-κB signaling pathway. It inhibits the Na+/K+-ATPase pump, leading to the accumulation of intracellular sodium and subsequent activation of NF-κB. The activated NF-κB pathway induces the transcriptional downregulation of DDX41. | ||||||
NSC697923 | 343351-67-7 | sc-391107 sc-391107A | 1 mg 5 mg | $15.00 $52.00 | 3 | |
NSC 697923, a small molecule compound, acts as an indirect inhibitor of DDX41 by affecting the cGAS-STING signaling axis. It inhibits TBK1, a downstream effector of cGAS, preventing the phosphorylation of STING and downstream signaling events. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide, an immunomodulatory agent, acts as an indirect inhibitor of DDX41 by influencing the DHODH-IRF3 signaling axis. It inhibits DHODH, disrupting de novo pyrimidine synthesis and leading to reduced IRF3 phosphorylation. The impaired DHODH-IRF3 signaling axis attenuates DDX41 expression, providing a unique approach for modulating DDX41 activity by targeting metabolic pathways connected to its immune signaling regulation. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103, a dual PI3K and mTOR inhibitor, acts as an indirect inhibitor of DDX41 by influencing the PI3K-AKT-mTORC1 signaling axis. It inhibits PI3K, preventing the phosphorylation of AKT and downstream mTORC1 activation. The impaired PI3K-AKT-mTORC1 signaling axis leads to reduced expression of DDX41, as it is regulated by this pathway. | ||||||
TAK 715 | 303162-79-0 | sc-362799 sc-362799A | 10 mg 50 mg | $185.00 $781.00 | ||
TAK-715, a p38 MAPK inhibitor, acts as an indirect inhibitor of DDX41 by modulating the p38 MAPK signaling pathway. It inhibits p38 MAPK, preventing its downstream signaling events. The disrupted p38 MAPK pathway leads to reduced expression of DDX41, as it is regulated by this pathway. | ||||||